RealTime Dynamix™: Atopic Dermatitis US Q3 2018 Spotlight

RealTime Dynamix™: Atopic Dermatitis US Q3 2018 Spotlight

atopic dermatitis market

While dermatologists continue to report high satisfaction with the first FDA approved biologic, there is still a large unmet need for new pharmacologic treatments for atopic dermatitis. Sanofi/Regeneron’s Dupixent continues to exceed expectations and current users remain extremely satisfied with the first biologic approved to treat moderate-to-severe atopic dermatitis, according to RealTime Dynamix: Atopic Dermatitis US. Lack of insurance coverage continues to be the most commonly cited barrier to use, while out-of-pocket costs have become a growing concern amongst dermatologists. View the spotlight below for complimentary highlights from the Q3 report.

Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.

Atopic Dermatitis

All company, brand or product names and logos in this document are trademarks of their respective holders.

2018-08-17T13:35:46+00:00